# George S Vassiliou

## List of Publications by Year in descending order



| | | | |
|---|---|---|---|
| 93 papers | 11,388 citations | 81900 39 h-index | 46799 89 g-index |
| 108 all docs | 108 docs citations | 108 times ranked | 15586 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | TheCADM1tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11. Blood Advances, 2022, 6, 386-398. | 5.2 | 3 |
| 2 | NPM1 gene mutations can be confidently identified in blood DNA months before de novo AML onset. Blood Advances, 2022, 6, 2409-2413. | 5.2 | 3 |
| 3 | Npm1 Haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice. Blood Advances, 2022, , . | 5.2 | 1 |
| 4 | The longitudinal dynamics and natural history of clonal haematopoiesis. Nature, 2022, 606, 335-342. | 27.8 | 136 |
| 5 | Clonal dynamics of haematopoiesis across the human lifespan. Nature, 2022, 606, 343-350. | 27.8 | 160 |
| 6 | A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility forÂtesting interventions. Blood, 2022, 140, 1774-1789. | 1.4 | 13 |
| 7 | Controlled masking and targeted release of redox-cycling ortho-quinones via a Câ€“C bond-cleaving 1,6-elimination. Nature Chemistry, 2022, 14, 754-765. | 13.6 | 18 |
| 8 | STAT1 is essential for HSC function and maintains MHCIIhi stem cells that resist myeloablation and neoplastic expansion. Blood, 2022, 140, 1592-1606. | 1.4 | 15 |
| 9 | Clonal hematopoiesis is not significantly associated with COVID-19 disease severity. Blood, 2022, 140, 1650-1655. | 1.4 | 10 |
| 10 | Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis. Nature Genetics, 2022, 54, 1155-1166. | 21.4 | 109 |
| 11 | Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML. Leukemia, 2022, 36, 2032-2041. | 7.2 | 2 |
| 12 | Mouse Models of Myeloid Malignancies. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a035535. | 6.2 | 3 |
| 13 | KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements. Leukemia, 2021, 35, 1012-1022. | 7.2 | 26 |
| 14 | The PML-RARA fusion is not detectable in historical blood samples of acute promyelocytic leukaemia patients. Annals of Hematology, 2021, , 1. | 1.8 | 0 |
| 15 | Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature, 2021, 593, 597-601. | 27.8 | 531 |
| 16 | SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3-ITDâ€“mutant AML. Blood Advances, 2021, 5, 2412-2425. | 5.2 | 10 |
| 17 | Clinical relevance of clonal hematopoiesis in persons aged â‰¥80 years. Blood, 2021, 138, 2093-2105. | 1.4 | 37 |
| 18 | METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation. Molecular Cell, 2021, 81, 3323-3338.e14. | 9.7 | 153 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression. Nature Genetics, 2021, 53, 1443-1455. | 21.4 | 19 |
| 20 | The Cancer Therapy-Related Clonal Hematopoiesis Driver Gene Ppm1d Promotes Inflammation and Non-Ischemic Heart Failure in Mice. Circulation Research, 2021, 129, 684-698. | 4.5 | 42 |
| 21 | Analysis pipelines for cancer genome sequencing in mice. Nature Protocols, 2020, 15, 266-315. | 12.0 | 25 |
| 22 | HBO1 is required for the maintenance of leukaemia stem cells. Nature, 2020, 577, 266-270. | 27.8 | 105 |
| 23 | PiggyBac mutagenesis and exome sequencing identify genetic driver landscapes and potential therapeutic targets of EGFR-mutant gliomas. Genome Biology, 2020, 21, 181. | 8.8 | 18 |
| 24 | IL2RA Promotes Aggressiveness and Stem Cellâ€“Related Properties of Acute Myeloid Leukemia. Cancer Research, 2020, 80, 4527-4539. | 0.9 | 12 |
| 25 | meCLICK-Seq, a Substrate-Hijacking and RNA Degradation Strategy for the Study of RNA Methylation. ACS Central Science, 2020, 6, 2196-2208. | 11.3 | 31 |
| 26 | Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML. Nature Communications, 2020, 11, 1407. | 12.8 | 13 |
| 27 | Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition. Blood, 2020, 136, 2442-2456. | 1.4 | 59 |
| 28 | Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow. Cell Reports, 2020, 30, 739-754.e4. | 6.4 | 32 |
| 29 | Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science, 2020, 367, 586-590. | 12.6 | 145 |
| 30 | Home and away: clonal hematopoiesis in sibling transplants. Blood, 2020, 135, 1511-1512. | 1.4 | 3 |
| 31 | RNAmut: robust identification of somatic mutations in acute myeloid leukemia using RNA-sequencing. Haematologica, 2020, 105, e290-e293. | 3.5 | 13 |
| 32 | Concordance for clonal hematopoiesis is limited in elderly twins. Blood, 2020, 135, 269-273. | 1.4 | 38 |
| 33 | Evi1 Counteracts Anti-Leukemic and Stem Cell Inhibitory Effects of All-Trans Retinoic Acid on Flt3-ITD/Npm1c-Driven Acute Myeloid Leukemia Cells. Biomedicines, 2020, 8, 385. | 3.2 | 4 |
| 34 | Triple-mutant AML: too clever by HLF?. Blood, 2019, 134, 222-224. | 1.4 | 1 |
| 35 | Genetic modification of primary human B cells to model high-grade lymphoma. Nature Communications, 2019, 10, 4543. | 12.8 | 36 |
| 36 | SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness. Scientific Reports, 2019, 9, 9139. | 3.3 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia. Blood, 2019, 134, 383-388. | 1.4 | 14 |
| 38 | Genome-scale drop-out screens to identify cancer cell vulnerabilities in AML. Current Opinion in Genetics and Development, 2019, 54, 83-87. | 3.3 | 3 |
| 39 | Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. Journal of Experimental Medicine, 2019, 216, 966-981. | 8.5 | 91 |
| 40 | PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice. Nature Communications, 2019, 10, 1415. | 12.8 | 37 |
| 41 | TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells. Genome Research, 2019, 29, 564-575. | 5.5 | 66 |
| 42 | The curious incident of TdT-mediated mutations in AML. Blood, 2019, 134, 2229-2231. | 1.4 | 5 |
| 43 | The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia. Nature Communications, 2019, 10, 5351. | 12.8 | 71 |
| 44 | Targeting MEK in vemurafenib-resistant hairy cell leukemia. Leukemia, 2019, 33, 541-545. | 7.2 | 26 |
| 45 | Recurrent histone mutations in Tâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2019, 184, 676-679. | 2.5 | 7 |
| 46 | Mutational Synergy Coordinately Remodels Chromatin Accessibility, Enhancer Landscape and 3-Dimensional DNA Topology to Alter Gene Expression during Leukemia Induction. Blood, 2019, 134, 278-278. | 1.4 | 2 |
| 47 | Pharmacological Inhibition of the RNA m6a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia. Blood, 2019, 134, 403-403. | 1.4 | 18 |
| 48 | Genetic Vulnerabilities of DNMT3AR882H in Myeloid Malignancies. Blood, 2019, 134, 111-111. | 1.4 | 8 |
| 49 | Abstract 3841: Therapeutic targeting ofFLT3mutations in AML via menin-MLL1 and FLT3 inhibition. , 2019, , . | | 0 |
| 50 | Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. Blood, 2018, 131, 1639-1653. | 1.4 | 114 |
| 51 | Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature, 2018, 554, 62-68. | 27.8 | 328 |
| 52 | Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. Blood, 2018, 131, 649-661. | 1.4 | 70 |
| 53 | Clonal haematopoiesis is not prevalent in survivors of childhood cancer. British Journal of Haematology, 2018, 181, 537-539. | 2.5 | 12 |
| 54 | SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. Nature Communications, 2018, 9, 5378. | 12.8 | 60 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell, 2018, 23, 700-713.e6. | 11.1 | 272 |
| 56 | Combined Influence of B-Cell Receptor Rearrangement and Somatic Hypermutation on B-Cell Class-Switch Fate in Health and in Chronic Lymphocytic Leukemia. Frontiers in Immunology, 2018, 9, 1784. | 4.8 | 22 |
| 57 | Prediction of acute myeloid leukaemia risk in healthy individuals. Nature, 2018, 559, 400-404. | 27.8 | 617 |
| 58 | Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nature Medicine, 2018, 24, 1167-1177. | 30.7 | 157 |
| 59 | UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs. Nature Genetics, 2018, 50, 883-894. | 21.4 | 117 |
| 60 | Abstract 391: Evolutionary trajectories andKRASgene dosage define pancreatic cancer phenotypes. , 2018, , . | | 0 |
| 61 | High Prevalence of PPM1D Mutations in Therapy-Related AML/MDS Is Due to Context-Specific Clonal Hematopoiesis. Blood, 2018, 132, 746-746. | 1.4 | 0 |
| 62 | Genome-wide transposon screening and quantitative insertion site sequencing for cancer gene discovery in mice. Nature Protocols, 2017, 12, 289-309. | 12.0 | 41 |
| 63 | Enhancing the genome editing toolbox: genome wide CRISPR arrayed libraries. Scientific Reports, 2017, 7, 2244. | 3.3 | 35 |
| 64 | A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes. Nature Genetics, 2017, 49, 730-741. | 21.4 | 53 |
| 65 | Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia. Blood, 2017, 130, 1911-1922. | 1.4 | 63 |
| 66 | Design and Application of Multiplex PCR Seq for the Detection of Somatic Mutations Associated with Myeloid Malignancies. Methods in Molecular Biology, 2017, 1633, 87-99. | 0.9 | 1 |
| 67 | Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib. Science Translational Medicine, 2017, 9, . | 12.4 | 33 |
| 68 | Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature, 2017, 552, 126-131. | 27.8 | 833 |
| 69 | Rapid parallel acquisition of somatic mutations after <scp>NPM</scp>1 in acute myeloid leukaemia evolution. British Journal of Haematology, 2017, 176, 825-829. | 2.5 | 3 |
| 70 | JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics. Blood Advances, 2017, 1, 968-971. | 5.2 | 42 |
| 71 | Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. Blood, 2016, 128, e1-e9. | 1.4 | 49 |
| 72 | JAK2 V617F clonal disorders: fate or chance?. Blood, 2016, 128, 1032-1033. | 1.4 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discovery, 2016, 6, 1166-1181. | 9.4 | 171 |
| 74 | Identification of a germline F692L drug resistance variant in cis with Flt3-internal tandem duplication in knock-in mice. Haematologica, 2016, 101, e328-e331. | 3.5 | 5 |
| 75 | Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia. Science Advances, 2016, 2, e1600760. | 10.3 | 90 |
| 76 | A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. Cell Reports, 2016, 17, 1193-1205. | 6.4 | 556 |
| 77 | Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related Clonal Hemopoiesis. Cell Reports, 2015, 10, 1239-1245. | 6.4 | 443 |
| 78 | Effect of Mutation Order on Myeloproliferative Neoplasms. New England Journal of Medicine, 2015, 372, 601-612. | 27.0 | 467 |
| 79 | Aging as a driver of leukemogenesis. Science Translational Medicine, 2015, 7, 306fs38. | 12.4 | 42 |
| 80 | CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13982-13987. | 7.1 | 172 |
| 81 | A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. Journal of Experimental Medicine, 2015, 212, 1551-1569. | 8.5 | 35 |
| 82 | A conditional piggyBac transposition system for genetic screening in mice identifies oncogenic networks in pancreatic cancer. Nature Genetics, 2015, 47, 47-56. | 21.4 | 77 |
| 83 | Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol. Haematologica, 2015, 100, 214-222. | 3.5 | 43 |
| 84 | Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?. DMM Disease Models and Mechanisms, 2014, 7, 941-951. | 2.4 | 148 |
| 85 | Capturing needles in haystacks: a comparison of B-cell receptor sequencing methods. BMC Immunology, 2014, 15, 29. | 2.2 | 62 |
| 86 | A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention. Cancer Cell, 2013, 24, 15-29. | 16.8 | 183 |
| 87 | Network properties derived from deep sequencing of human B-cell receptor repertoires delineate B-cell populations. Genome Research, 2013, 23, 1874-1884. | 5.5 | 128 |
| 88 | Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia. Blood, 2013, 121, 2289-2300. | 1.4 | 72 |
| 89 | Detection of cytoplasmic nucleophosmin expression by imaging flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2012, 81A, 896-900. | 1.5 | 15 |
| 90 | Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nature Genetics, 2011, 43, 470-475. | 21.4 | 194 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | PiggyBac Transposon Mutagenesis: A Tool for Cancer Gene Discovery in Mice. Science, 2010, 330, 1104-1107. | 12.6 | 217 |
| 92 | An acquired translocation in JAK2 Val617Phe-negative essential thrombocythemia associated with autosomal spread of X-inactivation. Haematologica, 2006, 91, 1100-4. | 3.5 | 3 |
| 93 | Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, The, 2005, 365, 1054-1061. | 13.7 | 3,100 |